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Background: The MANTA vascular closure device (VCD) is dedicated to large bore
access closure and associated with favorable results in selected study populations.
Anatomical predictors for access site complications are lacking.
Aim: To evaluate MANTA in a real-world population and identify predictors for vas-
cular complications.
Methods: All patients undergoing transfemoral transcatheter aortic valve replacement
(TAVR) between January 2016 and May 2020 with MANTA closure were included.
Baseline characteristics were collected, pre-procedural computed tomography and post-
deployment femoral angiograms were analyzed for anatomical differences. The primary
endpoint was a composite of access site related major and minor vascular complications
at 30 days follow-up according to the VARC-2 definitions. Secondary endpoints included
bleeding, time to hemostasis, procedural length and incomplete arteriotomy closure or
arterial occlusion by angiography. A Cox proportional hazards model was used to com-
pare all-cause mortality for patients with and without an access site complication.
Results: The 512 patients underwent TAVR with MANTA access closure. Median age
was 80 (IQR 75–85), 53% was male, median BMI was 26.4 kg/m2 (IQR 23.4–29.7).
Access site related major- or minor vascular complication occurred in 20 (4%) and
23 (4%) of patients respectively. Median time to hemostasis was 42 s (IQR 28–98).
Post deployment angiogram showed an occlusion in 24 patients (5%), incomplete clo-
sure in 60 patients (12%) or both in three patients (1%). Of these 87 patients,
36 (41%) had a vascular complication. Femoral artery diameter (OR 0.70 [0.53–0.93]),
low- (OR 3.47 [1.21–10.00]) and high (OR 2.43 [1.16–5.10]) arteriotomies were inde-
pendent predictors for vascular complications.
Conclusion: In this contemporary TAVR population, access-site related complica-
tions occurred in 8% of patients and were mainly due to percutaneous closure
device failure. Small artery diameter and off-target punctures were independent
predictors.
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1 | INTRODUCTION
Transcatheter aortic valve replacement (TAVR) is a valuable treatment
option for patients with severe aortic stenosis across the entire surgi-
cal risk spectrum.1-6 Over the past decade, transcatheter heart valve
(THV) design iterations, increased operator experience and centraliza-
tion of care in heart valve centers of excellence have decreased inci-
dences of vascular complications after TAVR.7,8 Nonetheless, major
vascular complications remain relevant with a 2–15% incidence
depending on the patient profiles at risk.3,5,6,9 The majority of these
complications involve the large bore sheath access site or ipsilateral
iliac artery and include vessel rupture, perforation, occlusion, dis-
section and pseudo-aneurysms.10,11 Vascular complications are not
benign and could form a limitation for younger patients undergoing
TAVR, considering their more active lifestyles.
MANTA (Teleflex, Wayne, PA, USA) is a plug-based VCD, dedi-
cated to large bore vascular closure. It consists of a poly-lactic cog-
lycolic toggle within the artery attached to a bovine collagen plug,
exterior to the vessel wall, which is tampered down by a stainless
steel lock.12 After TAVR and endovascular aneurysm repair MANTA
has been shown to be safe and effective: major vascular complications
occurred in 1.9–4.2% of cases and median time to hemostasis varied
from 19–24 s.13,14 However, these trials were performed in highly
selected populations and do not per se reflect the contemporary
TAVR population with a high burden of peripheral vascular disease
and morbid obesity.
Goal of the present study was to evaluate safety and efficacy of
MANTA closure in a contemporary TAVR population and to identify
predictors for access site vascular complications.
2 | METHODS
2.1 | Study population and investigational device
All patients who had MANTA closure of the femoral artery after TAVR
in the Erasmus University Medical Center from January 2016 until
May 2020 were included. Patients were discussed by the local multi-
disciplinary heart team and consented to data collection upon their
first outpatient visit. All data were prospectively collected and stored
in an anonymized secured database. The study was conducted in
accordance with the principles of the Declaration of Helsinki and did
not fall under the scope of the Medical Research Involving Human
Subjects Act per Institutional Review Boards' review.
MANTA mode of operations is described elsewhere.12 In brief, prior
to large sheath insertion the distance of the subcutaneous tract to the
vessel wall is measured with a dedicated sizing tool. At the end of the
procedure, the large sheath is exchanged for a dedicated MANTA sheath
to receive the toggle-plug assembly. The entire unit is then removed up
to the predetermined arteriotomy depth and the puncture site is sand-
wiched between the toggle and plug, which are connected through a
radiopaque stainless-steel lock. MANTA is available in a 14 Fr and 18 Fr
version for 10-14F and 14-22F outer diameter sheaths respectively.12
2.2 | Study procedures
All patients underwent preprocedural planning with multislice CT-
scanning. The 3mensio (Pie Medical, Maastricht, NL) software was
used to analyze the iliofemoral arterial tree, including minimal diame-
ter and calcifications.
Femoral punctures were ultrasound guided: the femoral bifurca-
tion was identified and the actual puncture was obtained in real-time
in a segment of the common femoral artery without anterior wall cal-
cification. Of note, no micropuncture technique was involved. During
MANTA-deployment target activated clotting time (ACT) was <200 s
and systolic blood pressure < 160 mmHg. Nitrates and protamine
were used per operator's discretion. After MANTA deployment, a
selective femoral angiogram via radial or contralateral femoral arterial
access was made under a 300 oblique projection to ensure hemostasis
and rule out vascular occlusions.
All post-deployment angiograms were analyzed off-line, the first
image after deployment was scored for angiographical success,
irrespective of maneuvers performed thereafter. Angiographical success
was defined as good flow towards the superficial and deep femoral
artery and absence of any extravasation or vascular occlusion. Cases
that were equivocal were double-read. Of note, no angiographical suc-
cess does therefore not per se equal a vascular complication (e.g., most
often manual compression would suffice). Additionally, CAAS software
(PIE medical, Maastricht, NL) was used to measure the length between
the bifurcation and arteriotomy (puncture height) as identified by the
radiopaque stainless steel lock of the MANTA device. (Figures 1).
2.3 | Outcomes and definitions
All patients had follow-up visits at 30 days, 1 year and 3 years post
TAVR. Adverse events were classified according to Valve Academic
Research Consortium-2 (VARC-2) definitions.15
Calcification of the common femoral artery (CFA) was scored
according to longitudinal and circumferential calcium distribution (either
none, < 1 cm and < 1800, > 1 cm and < 1800 or > 1800). The sheath to
femoral artery ratio (SFAR) was defined as the ratio between the mini-
mal diameter of the iliofemoral trajectory by the maximum outer
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diameter of the sheath according to the manufacturer. Puncture height
was expressed categorically: below the bifurcation, between the bifurca-
tion and 2 cm above and higher than 2 cm. The MANTA-dedicated 8 Fr
puncture location dilator was used to measure the length of the subcu-
taneous track from skin to arteriotomy.
2.4 | Statistical analysis
All descriptive are presented as mean and standard deviation or as
median and interquartile range depending on normality; normality was
assessed through Shapiro-Wilks test. Categorical variables are presented
as counts and percentages. To compare all-cause mortality at 1 year
follow-up for patients with and without an access site complication we
performed a Cox proportional hazards model including age and surgical
risk (STS-PROM). We reported hazard ratio and 95% confidence interval.
To identify anatomical predictors for clinically relevant vascular
complications, we performed multivariate logistic regression with
covariates that were based on clinical perspective and had p < .010 on
univariate analysis. We looked at THV design rather than SFAR con-
sidering the use of expandable delivery sheaths. Predictors are
described as odds ratio with 95% confidence intervals. All statistical
analyses were performed using SPSS version 25.0 (IBM Corporation,
Chicago, Illinois).
F IGURE 1 Measuring
puncture height using CAAS
software. The distance between
A and A' was measured in
centimeters. Left: puncture above
the bifurcation. The radiopaque
lock marks where the MANTA
was deployed. Right, puncture at
the height of the bifurcation
[Color figure can be viewed at
wileyonlinelibrary.com]
F IGURE 2 Angiographical findings, bail-outs and vascular complications with MANTA. VARC-2, valve academic research consortium-2; VCD,
vascular closure device [Color figure can be viewed at wileyonlinelibrary.com]
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3 | RESULTS
3.1 | Study population and characteristics
From January 2016 until May 2020, 830 patients underwent transfemoral
TAVR of whom 284 (34%) had large bore access closure with double
ProGlide (Abbott Vascular, Abbott Park, Illinois) and 512 (62%) with
MANTA.
Thirty-day follow-up was complete in all patients. 53% of patients
were male, median age was 80 years (IQR 75–85) and median body
mass index was 26 kg/m2 (IQR 23–30). Median Society of Thoracic Sur-
geons' score was 3.3% (IQR 2.1–5.4). There was a trend towards smaller
minimal diameter in the access-site complications group (7.1 ± 1.5
vs. 7.5 ± 1.3, p = .10) but no difference in calcification severity in the
CFA. Punctures in the access-site complications group were higher
above the bifurcation than the reference group (median puncture height
2.3 cm (IQR 1.2–3.7) vs. 1.6 cm (IQR 0.9–2.7), p = .01) (Table 1).
3.2 | Clinical outcomes
The primary composite endpoint of any access site related vascular
complication occurred in 43 of 512 patients (8%). A major access-site
related vascular complication occurred in 20 (4%) of patients: five
TABLE 1 Baseline and procedural characteristics
Overall No access-site complication Access-site complication
n = 512 n = 469 n = 43 p value
Age (years) 80 [75–85] 80 [75–85] 80 [76–85] .94
Male gender 272 (53) 254 (54) 18 (42) .17
Body mass index (kg/m2) 26.4 [23.4–29.7] 26.3 [23.4–29.7] 27.7 [24.5–30.8] .16
Creatinin (mmol/L) 95 [76–118] 95 [76–118] 102 [82–127] .24
Hypercholesterolemia 298 (58) 272 (58) 26 (60) .67
Hypertension 365 (71) 331 (71) 34 (79) .32
Type 1 or 2 diabetes 151 (29) 139 (30) 12 (28) .88
Peripheral artery disease 148 (29) 138 (29) 10 (23) .50
Minimal diameter access site (mm) 7.4 ± 1.3 7.5 ± 1.3 7.1 ± 1.5 .10
Calcification common femoral artery .35
• None 101 (20) 94 (20) 7 (16)
• Mild (≤1 cm, ≤180) 207 (40) 192 (41) 15 (35)
• Moderate (>1 cm, ≤180) 86 (17) 75 (16) 11 (26)
• Severe (>180) 109 (21) 99 (21) 10 (23)
European system for cardiac operative
risk evaluation II (%)
3.3 [1.9–5.8] 3.3 [1.9–5.8] 3.4 [1.9–5.9] .87
Society of Thoracic Surgeons' score (%) 3.3 [2.1–5.4] 3.2 [2.1–5.4] 3.6 [2.2–6.1] .54
Sheath size 16 [14–16] 16 [14–16] 16 [14–16] .39
Valve used .35
• Acurate neo 47 (9) 41 (9) 6 (14)
• Evolut R 110 (21) 101 (22) 9 (21)
• Evolut pro 112 (22) 106 (23) 6 (14)
• Lotus edge 46 (9) 39 (8) 7 (16)
• Sapien 3 195 (38) 180 (38) 15 (35)
• Jenavalve 2 (0) 2 (0) 0 (0)
Valve size 26 [25–29] 26 [25–29] 26 [25–27] .14
Puncture height (cm)a 1.7 [0.9–2.8] 1.6 [0.9–2.7] 2.3 [1.2–3.7] .01
Depth vessel (cm) 5.0 [4.5–6.0] 5 [4.5–6.0] 5.5 [4.5–6.0] .37
ACT before closure (s) 197 ± 40 196 ± 40 202 ± 50 .42
Systolic BP before closure (mmHg) 134 [120–146] 134 [120–146] 134 [125–150] .61
Note: Categorical variables are presented as numbers (percentage), continuous variables are presented as median [IQR] or mean ± SD.
Abbreviations: ACT, activated clotting time; BP, blood pressure.
aOnly punctures above femoral bifurcation.
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patients had an access-site perforation leading to a life-threatening or
major bleeding, eight patients had percutaneous closure device failure
leading to life-threatening or major bleeding, five patients had ipsilateral
lower extremity ischemia, one patient had a dissection of the superficial
femoral artery requiring vascular surgery and one patient had a pseudo-
aneurysm that required vascular surgery. A minor access-site related
vascular complication occurred in 23 (4%): one patient had an access-
site hematoma, 15 patients had percutaneous closure device failure, five
patients had an access-site dissection/occlusion and two patients had a
pseudo-aneurysm.(Supplementary Table 1).
Median time to hemostasis was 42 s (IQR 28–98). A histogram
showing the distribution is available in the supplementary section.
Access site bleeding occurred in 38 of 512 patients (7%). Access site
bleedings were life-threatening, major or minor in 1%, 3% and 4% of cases
respectively. Red blood cell transfusion was required in 11% of patients:
3% of patients required 1 unit of red blood cells, 5% required 2 units and
3% required more than 3 units of red blood cells (Table 2, Figure 2).
In patients with an access-site related complication 35 (81%) had
prolonged hospitalization (> 5 days) and 30-day mortality was 7%.
Adjusted for age and surgical risk, during the first year of follow up there
was no difference in all-cause mortality between patients with and with-
out an access-site complication (adjusted HR 1.55 [0.61–3.93], p = .36).
3.3 | Angiographical findings and bail-outs
Post-deployment femoral angiography was done in 97% of cases, which
confirmed angiographical success in 412 (80%). Nonetheless, seven cases
that had unremarkable angiograms had a clinically relevant vascular compli-
cation afterwards: three patients had late percutaneous closure device fail-
ure presumably due to late dislocation of collagen and/or toggle (one
TABLE 2 Angiographical and clinical outcomes (< 30 days)
Angiographical and clinical outcomes n = 512
Major vascular complication 33 (6)
• Access site related 20 (4)
Minor vascular complication 44 (9)
• Access site related 23 (4)
Life-threatening bleeding 17 (3)
• Access-site related 5 (1)
Major bleeding 17 (3)
• Access-site related 15 (3)
Minor bleeding 30 (6)
• Access-site related 18 (4)
RBC transfusion
• 0 units 452 (88)
• 1 unit 17 (3)
• 2 units 27 (5)
• ≥3 units 16 (3)
Median time to hemostasis (s)a 42 [28–98]
Median procedural length (min)b 66 [50–87]
Angiographical findings
• Success 412 (80)
• Occlusion 24 (5)
• Incomplete closure 60 (12)
• Occlusion and incomplete closure 3 (1)
• No femoral angiogram 13 (3)
Note: Categorical variables are presented as numbers (percentage),
continuous variables are presented as median [interquartile range].
aData available in 363/512 of cases.
bData available in 481/512 of cases.
F IGURE 3 Predictors for vascular complications after MANTA deployment. Both off-target punctures and smaller caliber vessel were
independent predictors for access site related vascular complications. OR – Odds ratio [Color figure can be viewed at wileyonlinelibrary.com]
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required surgery, one required a covered stent and one required prolonged
manual compression), two patients had a pseudo-aneurysm, one patient
had a sheath related injury prior to VCD-deployment and one patient had
a late occlusion of the common femoral artery requiring vascular surgery.
Of the 87 abnormal angiograms, 24 (27%) had an occlusion,
60 (69%) had incomplete arteriotomy closure and 3 (4%) had both. An
abnormal femoral angiogram required either no additional action (n = 11,
13%); prolonged manual compression (n = 23, 30%); balloon angioplasty
(n = 29, 38%); endovascular stenting (n = 18, 24%) or vascular surgery
(n = 6, 8%). There was one patient that had incomplete arteriotomy clo-
sure on angiography that was initially conservatively treated but later
developed a pseudo-aneurysm that required a thrombine-injection. In
total 36 out of 87 (41%) patients with an abnormal angiogram had a
VARC-2 defined vascular complication at 30 days follow-up. In the entire
cohort unplanned vascular surgery was required in 8 (1.5%) patients and
unplanned endovascular stenting in 20 (3.9%) patients.
3.4 | Predictors
Multivariate logistic regression showed that smaller minimal diameter
of the femoral artery (OR 0.81 95%-CI [0.54–0.99]; p = .015), punc-
tures on- or below the bifurcation (OR 3.47, 95-% CI [1.21–10.00];
p = .02) and high punctures >2 cm above the bifurcation (OR 2.43,
95-% CI [1.16–5.10]; p = .02) were independent predictors of access-
site related vascular complications.(Figure 3, Table 3).
There was no difference in the complication rate over time when
comparing the first 171 consecutive cases with cases 171–344 and
344–512. (6% vs. 8% vs. 11%, p = .39).
4 | DISCUSSION
Our real-world experience with MANTA in a TAVR cohort of
512 patients involved standardized use of multislice computed tomog-
raphy prior to the procedure, ultrasound-guided arterial access and
femoral angiography post MANTA deployment. The main findings can
be summarized as follows1: Access site related vascular complications
with MANTA occurred in 8% of cases (4% major vascular complica-
tions) and were mainly due to percutaneous closure device failure.2
Unplanned vascular surgery and covered stenting were required in
1.5% and 3.9% respectively.3 Femoral artery occlusion appeared in
5% of cases, and was typically resolved by balloon dilatation.4 Small
femoral artery diameter and high or low punctures independently
predicted vascular complications with MANTA.
4.1 | In perspective
MANTA is a plug based VCD and compares favorably to suture based
closure techniques. Our 8% overall and 4% major access site compli-
cation rates are lower or similar to what was reported for double
TABLE 3 Clinical- and anatomical predictors for access-site related vascular complications (VARC-2) n = 512
Univariate Multivariate
Variable OR 95% CI p value OR 95% CI p value
ACT at closure (per s increase) 1.00 [1.00–1.01] .42
BMI (per kg/m2 increase) 1.04 [0.98–1.10] .17
Femoral artery diameter (per mm increase) 0.81 [0.62–1.04] .10 0.70 [0.53–0.93] .01
Female sex 1.64 [0.87–3.09] .13
Moderate to severely calcified CFA (none/mild as reference) 1.57 [0.84–2.94] .16
Puncture height
• 0–2 cm 1.00
• < 0 cm (0–2 cm as reference) 3.42 [1.20–9.75] .02 3.47 [1.21–10.00] .02
• > 2 cm (0–2 cm as reference) 2.67 [1.29–5.56] .01 2.43 [1.16–5.10] .02
Systolic blood pressure at closure (per mmHg increase) 1.00 [0.99–1.02] .94
THV design
• Evolut R 26–29 1.00
• Evolut pro 26-29/R 34 (Evolut R as ref ) 0.54 [0.19–1.55] .25
• Sapien3 (Evolut R as ref) 0.82 [0.34–2.02] .67
• Lotus edge (Evolut R as ref) 1.77 [0.60–5.24] .30
• Acurate neo (Evolut R as ref) 1.45 [0.47–4.45] .52
Vessel depth 1.10 [0.88–1.37] .39
Note: Univariate- and multivariate logistic regression for access-site related vascular complications (according to VARC-2).
Abbreviations: ACT, activated clotting time; BMI, Body Mass Index; CI, confidence interval; CFA, Common femoral artery; THV, transcatheter heart valve;
OR, odds ratio.
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ProGlide in the CONTROL registry (19.9% overall and 1.9% major vas-
cular complications).11 Compared to previous retrospective analyses
with MANTA, that showed an incidence of access site related vascular
complication ranging from 9% - 14%, our 8% is at the lower bound of
the spectrum.16-18 Of note, the all-comers nature of this study implied
stretching of the boundaries as illustrated by the vessel diameter and
BMI that ranged outside the manufacturer instructions for use. In per-
spective to the selected populations of the CE Mark- and IDE trial that
showed median time to hemostasis of 19 and 24 s and incidence of
major vascular complications of 1.9% and 4.2%, our 4% major vascular
access complication rate and median time to hemostasis of 42 s attest
to good MANTA performance beyond a selective trial setting.13,14
Compared to the PRAGMATIC registry, we reported a much lower
vascular complication rate after TAVR (8% vs. 27%), still percutaneous
closure device failure remains the main cause of access site
complications.10
4.2 | Angiographical confirmation
The systematic angiographic control revealed incomplete closure or
transient occlusion in up to 20% of cases that were most often solved
by (manual) compression or ballooning. (Figure 4) Bail out maneuvers
with MANTA are limited and distinct from suture based techniques as
there is no safety wire to re-insert a sheath or accommodate another
VCD in case of percutaneous closure device failure. Bail-outs include
(manual or mechanical) compression, prolonged balloon dilatation, the
use of hemostatic matrix, endovascular stents and vascular surgery.
The use of a balloon to occlude the aorta for uncontrollable retroperi-
toneal bleeding can serve as a bridge to vascular surgery and is of
potential life-saving value, but was not needed in our series.19
In this trial, unplanned vascular surgery and covered stenting was
required in 1.5% and 3.9% respectively. Endovascular stenting of the
CFA comes at a risk of restenosis, stent fracture and precludes the
use of the CFA for future access.20,21 Notably, bail-out use of endo-
vascular stents was reported in 2.5–9.6% of cases in studies on
suture-based closure devices.11,22,23
4.3 | Arteriotomy location and vessel caliber
The radiopaque stainless steel lock of the MANTA device allowed to
accurately measure the exact puncture location on the femoral angio-
gram. Both low (i.e., at or below the femoral bifurcation) (OR 3.47,
p = .02) and high (> 2 cm above the femoral bifurcation) (OR 2.43,
p = .02) punctures were predictors for clinically relevant vascular com-
plications and should be avoided at all cost. Due to MANTA's intra-
arterial design, it is prone for vascular occlusions when deployed in
the superficial or deep femoral artery. High punctures have high risk
for retroperitoneal bleeds and are non-compressible against the femo-
ral head. MANTA closure should therefore be avoided in punctures
above the epigastric artery or below the femoral bifurcation. Arguably,
in the context of atherosclerotic disease and calcium, ultrasound guid-
ance may drive operators to higher puncture sites that may be free of
disease but less prone to manual compression.24 A study by Pitta
et al. suggested that a puncture technique based on anatomical land-
marks was off target in 13% of cases and associated with vascular
complications.25 Therefore, we believe ultrasound guided access
should be the method of choice to grant a vue appreciation of the
femoral bifurcation, calcium distribution and needle entry.
Angiographical confirmation after ultrasound guided access may prove
a valuable confirmatory double check, particularly in obese patients.
Apart from suboptimal puncture location, small vessel caliber was
associated with access site complications (OR 0.73 [0.54–0.99],
p = .04), this is in line with previous findings, where an SFAR threshold
>1.05 predicted a higher rate of major vascular complications.26
F IGURE 4 Possible findings on post-deployment femoral angiogram. From left to right: dissection, occlusion, incomplete hemostasis with
large amount of leakage, incomplete hemostasis with small amount of leakage [Color figure can be viewed at wileyonlinelibrary.com]
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5 | LIMITATIONS
This is a retrospective analysis with inherent selection bias, the deci-
sion for MANTA was per operators discretion, therefore during the
observational period also suture-based closures were applied. The
dataset captured the entire experience following its introduction. Fur-
thermore, the technology was applied beyond the boundaries of prior
prospective trials to help understand its potential in different anatomi-
cal phenotypes. The fact that we saw a stable complication rate over
time suggests that the adoption of a plug-based closure concept that
is mainstream for small bore closure is relatively straightforward with
large bore arteriotomies. A large randomized trial comparing MANTA
with suture based closure should add more perspective to the relative
pro and cons for the respective closure techniques overall and in par-
ticular settings such as small caliber vessels, obesity, calcifications
and sex.
6 | CONCLUSION
Access site related vascular complications with MANTA occur in 8%
of patients after TAVR and remain driven by percutaneous closure
device failure. Femoral angiograms should confirm VCD success post
deployment. Small caliber vessel and high or low punctures were inde-
pendently associated with access site complications.
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